Current Hematology News and Events

Current Hematology News and Events, Hematology News Articles.
Sort By: Most Relevant | Most Viewed
Page 1 of 20 | 769 Results
Measuring hemoglobin levels with AI microscope, microfluidic chips
A complete blood count can help ascertain the health of a patient and typically includes an estimate of the hemoglobin concentration, which can indicate several conditions, including anemia, polycythemia, and pulmonary fibrosis. In AIP Advances, researchers describe a AI-powered imaging-based tool to estimate hemoglobin levels. The setup was developed in conjunction with a microfluidic chip and an AI-powered automated microscope that was designed for deriving the total as well as differential counts of blood cells. (2021-02-23)

Surface testing for SARS-CoV2 in hematology/oncology settings reveals negligible detection
Researchers from Rutgers Cancer Institute of New Jersey, the state's only National Cancer Institute-designated Comprehensive Cancer Center, evaluated the frequency of SARS-CoV-2, the virus that causes COVID-19, on various environmental surfaces in outpatient and inpatient hematology/oncology settings located within Rutgers Cancer Institute and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility. The study revealed extremely low detection of SARS-CoV-2 on environmental surfaces across multiple outpatient and inpatient oncology areas, including an active COVID-19 floor. (2021-02-18)

Penn-developed CAR T therapy shows long-lasting remissions in non-hodgkin lymphoma
A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the chimeric antigen receptor (CAR) T cell therapy Kymriah™, researchers in Penn's Abramson Cancer Center reported today in the New England Journal of Medicine. (2021-02-17)

New biomarker may predict which pancreatic cancer patients respond to CD40 immunotherapy
Inflammation in the blood could serve as a new biomarker to help identify patients with advanced pancreatic cancer who won't respond to the immune-stimulating drugs known as CD40 agonists, suggests a new study from researchers in the Abramson Cancer Center of the University of Pennsylvania published in JCI Insight. (2021-02-04)

"Genetic SD-card": Scientists obtained new methods to improve the genome editing system
Researchers take a step in the development of genome editing technology. Currently it is possible to deliver genetic material of different sizes and structures to organs and tissues. This is the key to eliminating DNA defects and treating more patients. (2021-02-02)

FGF23 hormone from red blood cell precursors promotes hematopoietic stem cell mobilization
A Kobe University research group have discovered that fibroblast growth factor-23 (FGF23) produced by erythroblasts (cells that are the precursors of red blood cells) promotes the movement of hematopoietic stem cells into the peripheral blood. It is hoped that this discovery will enable new strategies to be developed for harvesting hematopoietic stem cells from bone marrow transplant donors. (2021-01-18)

Organizations collaborate to develop international von Willebrand Disease guidelines
The American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), National Hemophilia Foundation (NHF), and World Federation of Hemophilia (WFH) have developed joint clinical practice guidelines on the diagnosis and management of von Willebrand Disease (VWD), the world's most common inherited bleeding disorder. The guidelines were published today in Blood Advances. (2021-01-12)

New toolkit aims to improve quality of thrombosis data in COVID-19 trials
The ASH Research Collaborative (ASH RC) and the International Society of Haemostasis and Thrombosis (ISTH), two organizations with multidisciplinary expertise in blood clotting and bleeding disorders, have developed a toolkit to help clinical researchers from across medical disciplines design clinical trials that further the understanding of blood clotting events associated with COVID-19. (2020-12-17)

Cancer researchers identify potential new class of drugs to treat blood and bone marrow cancers
CLEVELAND - A new study by researchers in Cleveland Clinic's Taussig Cancer Institute and Lerner Research Institute describes a novel class of targeted cancer drugs that may prove effective in treating certain common types of leukemia. The results first appeared online in Blood Cancer Discovery. (2020-12-15)

PET imaging tracer proves effective for diagnosing and managing rare CNS B-cell lymphoma
Positron emission tomography (PET) imaging with 68Ga-pentixafor is an effective diagnostic tool for central nervous system (CNS) B-cell lymphoma, according to a proof-of-concept study published in the December issue of The Journal of Nuclear Medicine. (2020-12-10)

Circulating tumor DNA indicates risk of relapse after transplant in DLBCL patients
Many patients with diffuse large B-cell lymphoma (DLBCL) can be cured by a transplant using their own blood-forming stem cells, but as many as half eventually relapse. New research led by Dana-Farber Cancer Institute scientists suggests that patients whose blood or stem cell samples harbor tumor DNA are likely to relapse. (2020-12-07)

Study reveals surprising benefit of clonal hematopoiesis in allogeneic transplants
Clonal hematopoiesis (CH) is a recently identified condition in which mutations associated with blood cancers are detected in the blood of some healthy, usually older, individuals who don't have cancer. People with CH, while asymptomatic, have an elevated risk of developing blood cancers and other negative health outcomes, including heart attacks and strokes. (2020-12-05)

CAR T-cell therapy found highly effective in patients with high-risk non-Hodgkin lymphoma
A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting. (2020-12-05)

ASH: Off-the-shelf immune drug shows promise in aggressive multiple myeloma
A subcutaneous injection of the immune-boosting drug teclistamab was found to be safe and elicit responses in a majority of patients with relapsed or refractory multiple myeloma. (2020-12-05)

Donor stem cell transplant shown to improve survival in older patients with MDS
A new clinical trial offers the most compelling evidence to date that a donor stem cell transplant can improve survival rates for older patients with higher-risk myelodysplastic syndrome (MDS), Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting. (2020-12-04)

Octapharma presents results of study on Octagam® 10% for severe COVID-19 patients at ASH
Clinical research presented by Octapharma USA at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition will highlight the investigational use of high-dose Octagam® 10% [Immune Globulin Intravenous (Human)] for the most severe COVID-19 patients. Octapharma's intravenous immunoglobulin (IVIg) portfolio also will be featured in a study design poster focused on primary infection prophylaxis in patients with chronic lymphocytic leukemia during ASH, to be held virtually December 5 - 8 due to the coronavirus pandemic. (2020-12-02)

Study identifies patients with lung cancer most likely to respond to immunotherapy
In a new study, researchers at UCLA found patients with a particular type of HLA, a protein scaffold involved in presenting pieces of proteins described as peptides to the immune system, were particularly likely to benefit from immunotherapy. (2020-11-16)

Temple researchers discover drug resistance mechanism in leukemia, ID treatment strategy
In a new study, published online October 6 in the journal Cell Reports, scientists at the Lewis Katz School of Medicine at Temple University and researchers at multiple institutions in the United States and abroad, are the first to show that resistance to PARP inhibitors in leukemia can be overcome by combining PARP inhibition with blockade of TGFßR kinase activation. (2020-10-06)

The Josep Carreras Institute identifies a marker of poor evolution in Hodgkin's lymphoma
Dr. Manel Esteller, director of the Josep Carreras Leukemia Research Institute, published today in Blood journal, the discovery of a marker that allows predicting which patient with Hodgkin's lymphoma will present the aggressive clinical course, and will therefore be a case of special risk. (2020-09-15)

ASH releases new clinical practice guidelines on acute myeloid leukemia in older adults
Today, ASH published new guidelines to help older adults with acute myeloid leukemia (AML) and their health care providers make critical care decisions, including if and how to proceed with cancer treatment and the need for blood transfusions for those in hospice care. (2020-08-06)

Huntsman Cancer Institute illuminates potential new treatment in acute myeloid leukemia
In a study published in the journal Leukemia, lead author Ami Patel, MD, Huntsman Cancer Institute researcher and assistant professor in the Division of Hematology and Hematologic Malignancies at the University of Utah, showed that factors produced by bone marrow support cells allowed leukemia cells to survive treatment with quizartinib, a type of TKI. When quizartinib was combined with another TKI called dasatinib the alternative survival pathways were shut down, leading to more effective leukemia cell death. (2020-07-31)

Immunotherapy safe for patients with COVID-19, cancer
Preliminary data from researchers at the University of Cincinnati Cancer Center show that immunotherapy doesn't necessarily worsen complications for patients with both COVID-19 and cancer. (2020-07-20)

Moffitt researchers find dual inhibitor may be safer for CLL patients
Moffitt Cancer Center researchers want to learn more about how PI3K inhibitor therapy works with the body's immune system to determine if there are ways to predict or mitigate associated adverse effects. Their findings were published in the July 14 issue of Blood Advances, a journal of the American Society of Hematology. (2020-07-14)

For acute myeloid leukemia, genetic testing is often worth the wait
New tailored therapies offer exciting prospects for treating acute myeloid leukemia (AML), but taking advantage of them may require waiting a week or more for genetic testing before starting treatment, posing a dilemma for doctors and patients facing this deadly and often fast-moving disease. A new study bolsters the evidence that this approach is safe for most patients under careful clinical oversight. (2020-06-04)

Early treatment linked to reduced joint damage in young adults with severe hemophilia A
Children with severe hemophilia A who receive early prophylaxis are less likely to have joint damage in young adulthood than those who begin treatment later, according to a new study in Blood Advances. While data suggest earlier initiation of prophylaxis provides some protection compared to later initiation of prophylaxis, prophylaxis does not fully prevent joint damage. (2020-06-03)

New MDS subtype proposed based on presence of genetic mutation
In a special report published today in the journal Blood, an international working group of experts in myelodysplastic syndromes (MDS) proposes -- for the first time -- the recognition of a distinct subtype of MDS based on the presence of a nonheritable genetic mutation that causes the disease. The mutation is found in approximately one in every five patients with MDS. (2020-04-29)

Impact of donor lymphocyte infusion and intensified conditioning for relapsed/refractory leukemia
Leukemia relapse is still a major problem that impedes the success of hematopoietic cell transplant (HCT). Understanding the influence of treatment relevant variables in patients with refractory/relapsed acute leukemia (RRAL) is critical in the therapeutic decision making process. The population-based (the largest for haploidentical group) real-world data suggest that RRAL patients who manage to receive a ''total program'' with prophylactic/preemptive donor lymphocyte infusion (p/pDLI) and intensified conditioning can tolerate and have good chances for survival. (2020-04-15)

New prognostic tool helps leukemia patients plan for cancer treatment
A new prognostic tool predicts how long someone diagnosed with chronic lymphocytic leukemia (CLL) will be able to wait before starting cancer treatment. Researchers describe what they hope will become a point-of-care resource to help improve clinical decision making in a study published today in the journal Blood. (2020-04-08)

Case study: Treating COVID-19 in a patient with multiple myeloma
A case study of a patient in Wuhan, China, suggests that the immunosuppressant tocilizumab may be an effective COVID-19 treatment for very ill patients who also have multiple myeloma and other blood cancers. The report, published in Blood Advances, also suggests that blood cancer patients may have atypical COVID-19 symptoms. (2020-04-03)

The pros and cons of radiotherapy: Will it work for you?
Women undergoing radiotherapy for many cancers are more likely than men to be cured, but the side effects are more brutal, according to one of Australia's most experienced radiation oncology medical physicists. (2020-03-29)

Novel sepsis treatment enhances bacterial capture by neutrophil 'traps'
Researchers at Children's Hospital of Philadelphia (CHOP) have developed a novel treatment for sepsis - one of the leading causes of hospital death - that enhances the body's bacteria-capturing neutrophil extracellular traps (NETs) so that they more effectively capture infectious bacteria, resist degradation, and improve sepsis outcomes and survival. (2020-03-05)

Study finds gender disparities in hematology research success
Hematologists who complete a mentored training program experience greater levels of academic success than those who do not; however, a study published today in Blood Advances suggests a slight discrepancy in success levels between male and female hematologists. (2020-02-25)

New study finds cellular immunotherapy treatment associated with improved quality of life
Adult lymphoma patients whose disease was effectively treated with chimeric antigen receptor T-cell (CAR-T) therapy showed marked improvement on a variety of self-reported quality of life measures, according to a study published today in Blood Advances. The study offers evidence that CAR-T may not only extend cancer patients' survival, but also improve their quality of life after treatment. (2020-02-19)

City of Hope's Triplex vaccine reduces rate of CMV complications in transplant recipients
Patients who underwent a stem cell transplant and received the Triplex vaccine to prevent a type of herpes virus -- cytomegalovirus (CMV) -- from duplicating out of control were 50% less likely to develop health complications related to the virus than patients who did not take Triplex, according to a City of Hope-led study published today in Annals of Internal Medicine. (2020-02-10)

Single-cell sequencing of CLL therapy: Shared genetic program, patient-specific execution
Researchers at the CeMM Research Center for Molecular Medicine and partners in Budapest have studied the response to targeted leukemia therapy in unprecedented detail, using single-cell sequencing and epigenetic analysis. The paper published in Nature Communications uncovers a precise molecular program in patients with chronic lymphocytic leukemia (CLL) who start treatment with ibrutinib. While this program was shared by all patients, the speed of its execution differed widely. These results will help develop personalized strategies for managing CLL as a chronic disease. (2020-01-29)

Hope for patients with a rare genetic condition linked to severe infections
A research team sheds light on the mechanisms underlying chronic granulomatous disease. (2020-01-22)

Partnership with China prompts change in care for high-risk type of leukemia
Findings from a collaborative clinical trial have generated key insights into how targeted therapy should be used to treat leukemia driven by the Philadelphia chromosome. (2020-01-16)

Metabolic syndrome associated with increased risk of blood clot recurrence
People with metabolic syndrome -- a set of conditions including obesity, impaired glucose metabolism, elevated levels of fats and cholesterol in the blood, and high blood pressure - are more likely to experience recurrent blood clots, according to a new study published today in Blood Advances. Among patients diagnosed with a type of blood clot known as deep vein thrombosis (DVT), those who also had markers of metabolic syndrome were more likely to experience another venous thromboembolism (VTE) event. (2020-01-09)

New study finds blood clots more likely in children who receive PICCs
A new study provides convincing evidence that the use of peripherally inserted central catheters (PICCs) to administer medicine and draw blood in children is associated with a significantly increased risk of blood clots (known as venous thromboembolism or VTE) compared with central venous catheters (CVCs) placed directly into the neck or chest. (2020-01-07)

Researchers identify potential formula for blood cancer vaccine
Researchers at the Icahn School of Medicine at Mount Sinai have discovered a way to move precision immunotherapy forward by using genomics to inform immunotherapy for multiple myeloma, a blood cancer, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research, in December. (2019-12-19)

Page 1 of 20 | 769 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.